Ophthalmology CRO Services
KCAS Bio has experience in preclinical ophthalmic research, ranging from identification and procurement of compounds to determining efficacy, tolerability, and PK studies. We give you the milestone data you need to make important decisions in the early stages of your ophthalmologic product development.
Complex ophthalmology studies demand specialist expertise
When developing products for the eye, your project needs a CRO with specialist experience and expertise. Many studies in ophthalmology are complex, and for this reason you need a team which understands the assessments and can focus on the details. KCAS Bio knows how to provide high quality data for your ophthalmology drug development project.
Ophthalmology treatment research, by leading scientists
There are a couple major challenges typically associated with ophthalmology as it relates to bioanalysis, one of the main being limited access to fluids or tissues from a living eye. It is difficult to develop highly sensitive methods when you can’t use a lot of the matrix available. At KCAS Bio, we have a rich history of conducting studies on eye tissues and using unique techniques that make a little sample go a long way in our processes. We have leveraged our rich history of knowing how to build a sensitive method with a minimal amount of volume. Additionally, our pharma team has become well-known for their PK analysis of small molecules, which makes us a perfect candidate for ophthalmological studies, as typically the treatment of the eye is a small molecule.
We employ rigorous quality practices that go beyond our competition. Processes are continuously improved to ensure we consistently deliver a complete outsourcing experience to clients.
KCAS Bio provides high quality science and data services that have benefits for the entire drug development journey.
Agile, responsive, and easy to work with
We prepare and adapt our ophthalmology research based on a deep understanding of your drug development ambitions and wider business objectives.
KCAS Bio scientific insights
Blogs
Evolving CAR Therapies and the Growing Need for Robust PK/PD Monitoring Chimeric Antigen Receptor (CAR) based therapies are a growing and continuing focus in oncology and autoimmune therapeutic development. They utilize either self (autologous) or donor-derived (allogenic) T cells that are genetically engineered to target and kill cancerous or autoreactive…
Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In addition,…
News
KCAS Bio is proud to announce that its EU site (Lyon, France) has successfully renewed its Statement of Compliance with Good Laboratory Practices (GLP), confirming its ability to deliver GLP-grade bioanalytical methods in support of preclinical studies. Our GLP test facility was granted a Level of compliance “A”, reinforcing KCAS Bio’s capability to…
Tell us how we can help with your project
We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.